ArticleOrphanet journal of rare diseases2026
The disease burden and health-related quality of life in Chinese children with genetic cholestatic liver diseases: a cross-sectional study of progressive familial intrahepatic cholestasis and Alagille syndrome.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGenetic cholestatic liver diseases (GCLDs), including progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS), are rare inherited liver disorders that manifest in early childhood and lead to substantial morbidity and healthcare utilization. However, comprehensive data on their economic and humanistic burden in China are scarce.
methodsA cross-sectional study was conducted in 2024 among caregivers of GCLD children recruited from a major specialized referral center in China. Data were collected via an online questionnaire covering demographic and clinical profiles, diagnostic pathways, healthcare resource use, direct and indirect costs, and health-related quality of life (HRQoL) using the PedsQL™ Inventory. Caregiver burden was assessed using a Numerical Rating Scale. Univariate and multiple linear regression analyses were performed to identify factors associated with economic burden and HRQoL.
resultsAmong the 170 patients (PFIC: 41.2%, ALGS: 58.8%), misdiagnosis occurred in 62.4% of cases. The mean age at first visit was 3.9 months, while the mean age at confirmed diagnosis was 11.2 months. The average annual total cost was CNY 244,700 per patient, with direct medical, direct non-medical, and indirect costs accounting for 60.6%, 11.1%, and 28.3% respectively. Both univariate and multivariate analyses revealed that older age and higher family income were associated with better PedsQL scores, whereas disease severity, complications and more frequent follow-up significantly predicted poorer HRQoL.
conclusionsGCLDs confer a significant economic and quality-of-life burden on affected families in China, compounded by diagnostic delays and high out-of-pocket expenses. These findings underscore the need for improved diagnostic accuracy, early intervention, more coordinated rare disease care networks and enhanced psychosocial and financial support policies for this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.